Abstract
Chronic myelogenous leukemia (CML) is a malignant myeloproliferative disorder that originates from a pluripotent stem cell expressing the bcr‐abl oncogene. It is characterized by an abnormal release of the expanded, malignant stem cell clone from the bone marrow into the circulation. The stromal cell derived factor‐1 (SDF‐1) gene contains a common polymorphism, termed SDF1‐3′A, in an evolutionarily conserved segment of the 3′ untranslated region (UTR). In this work the SDF‐1 genotypes of 25 patients (9–82 years old) who had been clinically and hematologically diagnosed with CML were compared with those of 60 healthy donors. In addition, the nature of bcr‐abl hybrid mRNA and the association between demographic and hematological parameters were analyzed in cells from 12 CML patients (five women and seven men). All patients underwent blood collection during the chronic phase of disease after they received chemotherapy. b3a2 mRNA was detected in samples from eight of the CML patients and b2a2 mRNA was observed in four cases. An association between basophils and hemoglobin parameters was observed in that hemoglobin levels were higher in b2a2‐expressing patients, and mean basophil levels were higher in patients expressing b3a2. Four of the CML patients (16%) were homozygous for 3′A allele. Of the patients who showed the presence of bcr‐abl transcripts (N = 12), three presented the wt/wt genotype and nine were SDF1‐3′A carriers. Three of the latter were homozygous for this mutation. It is possible that the bcr‐abl fusion gene and the SDF1 genotype for 3′A allele have important implications for the pathogenesis of CML. J. Clin. Lab. Anal. 21:49–54, 2007. © 2007 Wiley‐Liss, Inc.
Keywords: chronic myeloid leukemia (CML), SDF1 chemokine, bcr‐abl
REFERENCES
- 1. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology 2003;132–152. [DOI] [PubMed] [Google Scholar]
- 2. Salesse S, Verfaillie CM. BCR/ABL‐mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. Mol Cancer Ther 2003;2:173–182. [PubMed] [Google Scholar]
- 3. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005;90:534–541. [PubMed] [Google Scholar]
- 4. Legdeur MC, Beelen RH, Schuurhuis GJ, et al. A functional study on the migration of human monocytes to human leukemic cell lines and the role of monocyte chemoattractant protein‐1. Leukemia 1997;11:1904–1908. [DOI] [PubMed] [Google Scholar]
- 5. Möhle R, Bautz F, Rafii S, Moore MAS, Brugger W, Kanz L. The chemokine receptor CXCR‐4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell‐derived factor‐1. Blood 1998;91:4523–4530. [PubMed] [Google Scholar]
- 6. Burger JA, Burger M, Kipps TJ. Chonic lymphocytic leukemia B cells express functional CXC4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94:3658–3667. [PubMed] [Google Scholar]
- 7. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez‐Ramos JC. The chemokine SDF‐1 is a chemoattractant for human hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111–120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell‐derived factor 1 (SDF‐1). J Exp Med 1996;184:1101–1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Lapidot T, Kollet O. The essential roles of the chemokine SDF‐1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune‐deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002;10:1992–2003. [DOI] [PubMed] [Google Scholar]
- 10. Winkler C, Modi W, Smith MW. Genetic restriction of AIDS pathogenesis by a SDF‐1 chemokine gene variant. Science 1998;118:681–688. [DOI] [PubMed] [Google Scholar]
- 11. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993;261:600–603. [DOI] [PubMed] [Google Scholar]
- 12. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differently expressed and regulated on human lymphocytes. Proc Natl Acad Sci USA 1997;94:1925–1930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Kirby LT, editor. DNA fingerprinting: an introduction. New York: Stocton Press; 1990.. [Google Scholar]
- 14. Amarante MK, De Lucca FL, Oliveira CEC, et al. Expression Of noncoding mRNA in human blood cells activated with synthetic peptide of HIV. Blood Cells Mol Dis 2005;35:286–290. [DOI] [PubMed] [Google Scholar]
- 15. Mazumder B, Seshadri V, Fox PL. Translational control by the 3′‐UTR: the ends specify the means. Trends Biochem Sci 2003;2:91–98. [DOI] [PubMed] [Google Scholar]
- 16. Thekkumkara TJ, Linas SL. Evidence for involvement of 3′‐untranslated region in determining angiotensin II receptor coupling specificity to G‐protein. Biochem J 2003;370:631–639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Geay JF, Buet D, Zhang Y, et al. p210BCR‐ABL inhibts SDF‐1 chemotatic response via alteration of CXCR4 signaling and down‐regulation of CXCR4 expression. Cancer Res 2005;65:2676–2683. [DOI] [PubMed] [Google Scholar]
- 18. Peled A, Hardan I, Trakhtenbrot L, et al. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin‐dependent migration and adhesion in response to the chemokine SDF‐1. Stem Cells 2002;20:259–266. [DOI] [PubMed] [Google Scholar]
- 19. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B‐cell lymphopoiesis and bone‐marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF‐1. Nature 1996;382:635–638. [DOI] [PubMed] [Google Scholar]
- 20. Cashman J, Clark‐Lewis I, Eaves A, Eaves C. Stromal‐derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood 2002;99:792–799. [DOI] [PubMed] [Google Scholar]
- 21. Fernandez‐Luna JL. Bcr‐Abl and inhibition of apoptosis in chronic myelogenous leukemia cells. Apoptosis 2000;5:315–318. [DOI] [PubMed] [Google Scholar]
- 22. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M‐bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991;78:1151–1161. [PubMed] [Google Scholar]
- 23. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m‐RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995;89:546–554. [DOI] [PubMed] [Google Scholar]
- 24. Zaccaria A, Martineli G, Testoni N, et al. Does the type of BCR‐ABL junction predict the survival of patients with chronic myeloid leukemia? Leuk Lymph 1995;16:231–236. [DOI] [PubMed] [Google Scholar]
- 25. Iikura M, Miyamasu M, Yamaguchi M, et al. Chemokine receptors in human basophils: inducible expression of functional CXCR4. J Leukoc Biol 2001;70:113–120. [PubMed] [Google Scholar]
- 26. Cabral AR, Mancilla MM, Sanchez MA, et al. Analysis of Bcr‐abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia. Gac Med Mex 2003;139:553–559. [PubMed] [Google Scholar]